Determination of torasemide in human plasma and its bioequivalence study by high-performance liquid chromatography with electrospray ionization tandem mass spectrometry  by Zhang, Lin et al.
Journal of Pharmaceutical Analysis 6 (2016) 95–102H O S T E D  B Y Contents lists available at ScienceDirectjournal homepage: www.elsevier.com/locate/jpa
Journal of Pharmaceutical Analysishttp://d
2095-17
(http://c
☆Peer
n Corr
nn Cor
macovig
210009
E-m
zunjianwww.sciencedirect.comOriginal ArticleDetermination of torasemide in human plasma and its bioequivalence
study by high-performance liquid chromatography with electrospray
ionization tandem mass spectrometry$
Lin Zhang a, Rulin Wang a, Yuan Tian a,n, Zunjian Zhang a,b,nn
a Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), China Pharmaceutical University, Nanjing 210009, China
b State Key Laboratory of Natural Medicine, China Pharmaceutical University, Nanjing 210009, Chinaa r t i c l e i n f o
Article history:
Received 23 June 2015
Received in revised form
10 November 2015
Accepted 10 November 2015
Available online 11 November 2015
Keywords:
Torasemide
HPLC–ESI–MS
Human plasma
Bioequivalence
Pharmacokineticsx.doi.org/10.1016/j.jpha.2015.11.002
79/& 2015 Xi'an Jiaotong University. Producti
reativecommons.org/licenses/by-nc-nd/4.0/).
review under responsibility of Xi'an Jiaotong
esponding author.
responding author at: Key Laboratory of Dru
ilance (Ministry of Education), China Pharm
, China.
ail addresses: tiancpu@sina.com (Y. Tian),
zhangcpu@hotmail.com (Z. Zhang).a b s t r a c t
A sensitive and selective method using high-performance liquid chromatography coupled with elec-
trospray ionization tandem mass spectrometry (HPLC–ESI–MS) to determine the concentration of tor-
asemide in human plasma samples was developed and validated. Tolbutamide was chosen as the internal
standard (IS). The chromatography was performed on a Gl Sciences Inertsil ODS-3 column
(100 mm2.1 mm i.d., 5.0 mm) within 5 min, using methanol with 10 mM ammonium formate (60:40, v/
v) as mobile phase at a ﬂow rate of 0.2 mL/min. The targeted compound was detected in negative io-
nization at m/z 347.00 for torasemide and 269.00 for IS. The linearity range of this method was found to
be within the concentration range of 1–2500 ng/mL (r¼0.9984) for torasemide in human plasma. The
accuracy of this measurement was between 94.05% and 103.86%. The extracted recovery efﬁciency was
from 84.20% to 86.47% at three concentration levels. This method was also successfully applied in
pharmacokinetics and bioequivalence studies in Chinese volunteers.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Torasemide (1-isopropyl-3-([4-(3-methyl-phenylamino) pyr-
idine]-3-sulfonyl) urea, CAS: 56211–40–6, Fig. 1A) is a new
high-efﬁciency loop diuretic, acting the same as other pyridine
sulfonylurea medications in blocking the Naþ–Kþ–2Cl carrier to
promote excretion of water on the thick ascending limb of the loop
of Henle [1]. It has been successfully used to treat oedematous
states associated with chronic congestive heart failure [2], renal
disease [3] and hepatic cirrhosis [4], and low-dose torasemide has
also been used to control arterial hypertension [5]. Research
proves that torasemide is safer and better tolerated than fur-
osemide in chronic heart failure patients and associated with a
trend in reducing all-cause mortality [6]. Lower incidences of ab-
normal serum potassium levels and hypotension were also ob-
served in patients receiving torasemide compared with those re-
ceiving other diuretics [7].on and hosting by Elsevier B.V. Th
University.
g Quality Control and Phar-
aceutical University, NanjingTorasemide is well absorbed and yields a bioavailability of
80%–90%. It is highly bound to protein (99%) [1]. The time of peak
reaches at 1 h, and the elimination half-life varies from 3 to 4 h.
Torasemide is metabolized by the hepatic cytochrome P450 sys-
tem, followed by both renal and non-renal excretion of metabo-
lites. The total amount of torasemide and metabolites in urine
is 83%, including 25% of torasemide, 11% of M1, 3% of M3, and 44%
of M5. Both M1 and M3 are active and probably contribute to the
diuretic action of torasemide [8]. Due to its high activity, a low
therapeutic dose is required.
A rapid, sensitive and reliable determination of torasemide in
human plasma is essential to evaluating its pharmacokinetics in
clinical trials and bioequivalence researches. Several methods have
been reported including gas chromatography–tandem mass
spectrography (GC–MS) [9], capillary zone electrophoresis (CZE)
[10], high-performance liquid chromatography–tandem ultraviolet
detection (HPLC–UV) [11–19] and high-performance liquid
chromatography–tandem electrochemical detection (HPLC–ED)
[20–22] to determine the concentration of torasemide as a single
analyte [9,12,18–21] or in combination with its important meta-
bolites [10,11,13–16] or with other diuretic drugs [23,24] in plasma
[11–19] or other biological samples [9,13,20–24]. Barroso et al. [9]
applied GC–MS to determine the concentration of torasemide in
human urine, which needs complicated preparation for derivati-
zation and is not suitable for bioequivalence studies of largeis is an open access article under the CC BY-NC-ND license
Fig. 1. Structure of (A) torasemide and (B) tolbutamide (IS).
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low sensitivity detectors [11–21]. These methods cannot detect the
low concentration points such as the last several points in
elimination phase, which will lead to inaccurate pharmacokinetic
parameters. In this case, high-performance liquid chromato-
graphy–tandem mass spectrometry (HPLC–MS) can be a better
option because it combines advantages of HPLC and MS, which
allows a rapid, sensitive and selective quantiﬁcation of drugs in
complex biological samples. However, there are only few reports
regarding the determination of torasemide concentration in hu-
man plasma using HPLC–MS.
In this study, a new method using HPLC–ESI–MS was devel-
oped to determine the concentration of torasemide in human
plasma rapidly, sensitively and selectively. This method was suc-
cessfully applied in pharmacokinetics and bioequivalence studies
in healthy Chinese volunteers.2. Materials and methods
2.1. Solvent and chemicals
Torasemide test tablets (Batch No: 441104) were supplied
by Jiangsu D&R Pharmaceutical Corporation (Taizhou, China).
Torasemide reference tablets (Batch No: 14052320) were pur-
chased from SZYY Group Pharmaceutical Limited (Taizhou, China).
Torasemide reference standard (Batch No: 100605–200401) was
obtained from National Institute for Food and Drug Control
(Beijing, China). Tolbutamide (internal standard, IS, Fig. 1B) stan-
dard (Batch No: 40716, 99.9% purity) was obtained from
Dr. Ehrenstorfer GmbH (Augsburg, Germany). Glibenclamide
standard (Batch No: 121633–201017) was obtained from National
Institute for the Control of Pharmaceutical and Biological Products
(Beijing, China). Methanol of chromatographic grade was pur-
chased from Merck, Germany. Ammonium formate, ethyl acetate
and hydrochloric acid were of analytical grade and purchased from
Nanjing Chemical Reagent Co., Ltd. (Nanjing, China). All other
chemicals were of analytical grade. Double distilled water was
prepared by passing through Milli-Q water System (Merck Milli-
pore, Massachusetts, U.S.).
2.2. Instrumentation and operation condition
2.2.1. Liquid chromatography
Liquid chromatography was performed using a Shimadzu LC-
10AD HPLC system consisting of an autosampler (SIL-HTc). Chroma-
tography was carried out with Gl Sciences Inertsil ODS-3 column
(100 mm2.1 mm i.d., 5.0 mm) using methanol: 10 mM ammonium
formate (60:40, v/v) as mobile phase. The temperatures of column
and autosampler were maintained at 40 °C and 15 °C, respectively.
The analysis was completed in 5 min at a ﬂow rate of 0.2 mL/min.
Data acquisition and processing was accomplished using Shimadzu
LC–MS solution software for LCMS-2010A system.2.2.2. Mass spectrometry
The ESI source was set at negative ionization mode. The
[M-H] , m/z 347.00 for torasemide and [M-H] , m/z 269.00 for
tolbutamide were selected as detecting ions, respectively. The
quantiﬁcation was performed via peak area. MS operating condi-
tions were optimized as follows: drying gas 1.5 L/min, curved
desolvation line (CDL) temperature 250 °C, block temperature
200 °C and probe voltage 1.65 kV.
2.3. Preparation of standard solution
Standard stock solutions of torasemide (1 mg/mL) and tolbu-
tamide (1 mg/mL) were prepared in methanol and stored at 4 °C
before use. Standard working solutions of torasemide for calibra-
tion curve and quality control (QC) were prepared by diluting
standard stock solution with mobile phase to 4, 20, 40, 200,
2000 ng/mL and 10 μg/mL. IS working solution was prepared by
diluting standard stock solution with mobile phase to 10 μg/mL.
2.4. Sample preparation
Sample preparation was performed by liquid–liquid extraction.
Two hundred microliters of plasma samples were transferred to
10 mL centrifuge tubes and extracted by 2.0 mL of ethyl acetate
after addition of 10 μL of IS working solution (10 μg/mL) and 20 μL
of 10% hydrochloric acid solution. The mixture was vortex-mixed
for 3 min, and then centrifuged at 3500 rpm for 10 min. 1.5 mL of
organic layer was transferred to another clean glass tube and
evaporated under a steady stream of nitrogen to dryness in a water
bath at 40 °C. The residue was re-dissolved in 200 μL of mobile
phase and vortexed for 30 s. Following centrifugation (16,000 rpm,
10 min), aliquots of 5 μL of the supernatant were injected into the
HPLC–ESI–MS system.
2.5. Calibration curve and QC samples
Calibration curves were prepared by spiking blank plasma with
appropriate amount of torasemide working solution mentioned
above to yield concentrations of 1, 3, 10, 50, 200, 800, 1500, 2000
and 2500 ng/mL. The following steps were the same as those de-
scribed in Section 2.4. The blank plasma samples (with or without
IS) were also analyzed to conﬁrm absence of interferences, but the
results for blank samples were not used as parts of the calibration
curves.
QC samples, which were analyzed at the same time with test
samples, were prepared at concentrations of 3 (low level), 800
(middle level) and 2000 ng/mL (high level). The total amount of
QC samples was no less than 5% of the test samples in the same
batch.
2.6. Method validation
The method was validated according to the bioanalytical
method validation guidance currently accepted by US Food and
Drug Administration (USFDA) [25].
2.6.1. Speciﬁcity
The speciﬁcity of this method was investigated by preparing
and analyzing 6 blank plasma samples from different sources of
individual humans. It was assessed by comparing the chromato-
grams obtained from blank plasma with those from the sample
spiked with torasemide at lower limit of quantitation (LLOQ). Each
blank sample was also tested for the visible interference.
2.6.2. Linearity, LLOQ and limit of determination (LOD)
Linearity was completed in 5 replicates at concentration levels
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curves were generated by plotting the peak area ratios of tor-
asemide to tolbutamide (IS) versus concentration of torasemide
and ﬁtted to the equation y¼bxþa by weighted least-squares
linearity regression (w¼1/y2), where y corresponds to the peak
area ratio of torasemide to the IS and x refers to the concentration
of torasemide added to plasma.
LLOQ was determined as the concentration with a signal-to-
noise ratio of 10. Standard calibrators should not deviate by more
than 15% of nominal concentrations, except at LLOQ where the
standard calibrator should not deviate by more than 20%. The LOD
was determined as the concentration with a signal-to-noise ratio
of 3.
2.6.3. Precision and accuracy
The intra-batch precision and accuracy was measured by ana-
lyzing 5 replicates plasma samples spiked with torasemide at each
QC level (3, 800 and 2000 ng/mL) in a batch, and the inter-batch
precision and accuracy was determined by analyzing 5 sets of
plasma samples spiked with torasemide at each QC level (3, 800
and 2000 ng/mL) in three consecutive batches on different days.
The concentration of each sample was calculated using standard
curve prepared and analyzed on the same day. The precision was
expressed as the relative standard deviation (%RSD), and the ac-
curacy was deﬁned as a percentage of the measured concentration
over the theoretical concentration. The acceptance deviation for
precision and accuracy should not exceed 15%.
2.6.4. Extraction recovery
The extraction recovery of torasemide was determined by
comparing corresponding peak area ratios of torasemide to IS
obtained from extracted plasma samples (As-r, n¼5) with those
from processed blank plasma samples added the same amount of
torasemide and IS standard solution (Ar-r, n¼2). This procedure
was repeated at three different concentrations of 3, 800 and
2000 ng/mL.
The extraction recovery of tolbutamide was determinedFig. 2. Negative ion electrospray mass scan speby comparing peak areas of IS obtained from extracted plasma
samples (As-is, n¼5) with those from processed blank plasma
samples added the same amount of IS standard solution (Ar-r, n¼2).
2.6.5. Stability
Stability was evaluated under different conditions that were set
during sample analysis. The stability of standard stock solution of
torasemide and IS was evaluated at 4 °C for 10 days. The stability of
standard working solution of torasemide and IS was evaluated at
room temperature for 8 h. The short-time stability of plasma samples
was evaluated at room temperature for 8 h. The residue stability was
evaluated by analyzing re-dissolved residue placed at room tem-
perature for 24 h and 48 h, respectively. The post-preparative stabi-
lity was evaluated by re-analyzing extracted plasma samples placed
in the autosampler at 15 °C for 24 h. The freeze and thaw stability
was evaluated by analyzing plasma sample undergoing freeze
(20 °C) and thaw (room temperature) cycles on three consecutive
days. The long-time stability of plasma samples was evaluated at
20 °C for 15 days. Every plasma sample stability was repeated
3 times at 3 concentration levels (3, 800, 2000 ng/mL), while stan-
dard solution stability was repeated 3 times only at LLOQ level.
2.6.6. Matrix effect
To assess ionization interference from endogenous compounds
co-eluted with the analyte, matrix effect was carried out. Matrix
effects of torasemide or IS were evaluated by comparing the peak
areas of torasemide or IS spiked with the post-extraction residue
of the blank plasma with those of standard solutions at three
concentration levels (3, 800, 2000 ng/mL). This procedure was
repeated 5 times. If the ratio was between 115% and 85%, an
exogenous matrix effect was negligible.
2.6.7. Co-eluting effect
As the retention time of torasemide and IS is close, torasemide
was eluted from HPLC column into the mass spectrometer at the
same time as the IS, which may affect the ionization of the
torasemide or IS. In other words, the mass spectrum response ofctra of (A) torasemide and (B) tolbutamide.
L. Zhang et al. / Journal of Pharmaceutical Analysis 6 (2016) 95–10298torasemide may decrease due to electrospray ionization compe-
titive inhibition, which may vary depending on the concentration.
Therefore, it is necessary to investigate the co-eluting effect. Co-
eluting effect of torasemide was calculated by comparing the peak
areas of torasemide with IS and without IS. Co-eluting effect of IS
was calculated by comparing the peak areas of IS with torasemide
and without torasemide. Three concentration levels (1, 800,
2500 ng/mL) were repeated 5 times. The acceptance deviation for
co-eluting effect should not exceed 15%.2.7. Method application
We recruited 24 healthy Chinese male volunteers aged from 18
to 40 years and with a BMI between 19 to 24. All the volunteers
gave their written consent for their participation in the study after
having been informed of all aspects of the study, especially the
potential risks. The study protocols were approved by Jiangsu
Province Hospital of Traditional Chinese Medicine (Nanjing, Chi-
na), in accordance with the principles of the Declaration of Hel-
sinki and the recommendations of the State Food and Drug Ad-
ministration of China.
The study was carried out with an open randomized, balanced,
two-period crossover study. Each volunteer received a single oral
dose of 10.0 mg of torasemide test tablets or reference tablets in a
random order in cycle, with 200 mL of water after an overnight
fast of 12 h. Venous blood samples were collected at the time of 0,
10, 20, 30, 45 min and 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 14.0
and 24.0 h after oral administration of the medicine. All samples
were collected into heparin tubes and immediately centrifuged at
3500 rpm for 15 min and stored at 20 ◦C until analysis.2.8. Pharmacokinetic and statistical analysis
Pharmacokinetic analysis and statistical analysis were per-
formed by DAS2.0 software. Pharmacokinetic parameter of tor-
asemide was estimated from the concentration–time data using
non-compartmental methods. Pharmacokinetic parameters, AUC
and Cmax, were used to evaluate bioequivalence through analysis
of variance and two one-side t tests after the natural logarithm
conversion. The Wilcoxon signed rank test was used for the non-
parametric analysis to determine differences in Tmax. The 90%
conﬁdence intervals of the T/R-ratios of logarithmically trans-
formed data were within the accepted range of 80%–125% for
AUC0-τ and AUC0-1, and 75%–133% for Cmax.Table 1
Extraction efﬁciency of several extraction reagents.
Reagents Acid-base properties Extraction efﬁciency (%)
Torasemide IS
Hexane Neutral Not found Not found
Cyclohexane Neutral Not found Not found
Ether Neutral Not found 8
Dichloromethane Neutral 4 64
Dichloromethane Base (50 μL of saturation
NaHCO3)
6 42
Dichloromethane Acid (50 μL of 10% hydrochloric
acid)
18 91
Ethyl acetate Neutral 28 56
Ethyl acetate Base (50 μL of saturation
NaHCO3)
35 35
Ethyl acetate Acid (50 μL of 10% hydrochloric
acid)
61 842.9. Incurred sample reanalysis
Several random samples from the highest plasma concentra-
tion closed to Tmax or the lowest plasma concentration at the end
of elimination phase were reanalyzed again in each assay period.
The percentage difference of the results was determined with the
equation (Repeat-Original)/Mean100%, where repeat and origi-
nal refers to the concentration of torasemide measured two times.
The acceptance criterion between two measurements should not
exceed 720% [26].3. Results and discussion
3.1. HPLC–MS method development
To develop a rapid, simple and sensitive method for determi-
nation of torasemide, different options were evaluated to optimize
chromatography separation and MS detection parameters.
The chromatography condition was optimized to improve sig-
nal, decrease base-line noise, avoid interference of matrix and
reduce run time. Optimization of chromatography conditions
included the option of columns type like Shimadzu Shim-pack
VP-ODS column (250 mm2.0 mm i.d., 4.6 mm), Gl Sciences
Inertsilph-3 column (100 mm2.1 mm i.d., 3.0 mm) or Gl Sciences
InertsilODS-3 column (100 mm2.1 mm i.d., 5.0 mm) and differ-
ent kinds and concentrations of mobile phase like water, formic
acid, ammonium formate and ammonium acetate together with
methanol in different proportions. All the columns provided ade-
quate response. However, Gl Sciences Inertsilph-3 column cannot
separate torasemide and endogenous compounds effectively, and
the endogenous compounds were still detected above 10 min,
which would have an effect on next sample assay. Shimadzu Shim-
pack VP-ODS almost provided a baseline separation of analytes
and endogenous compounds, but the retention time for the target
analyte was above 5 min. Thus, neither columns were considered
for further experiment. The best chromatography was achieved on
Gl Sciences Inertsil ODS-3 column within 5 min with good peak
shape, due to its small dead volume and excellent bonding and
endcapping techniques, and nearly having no interference on
analytes. In addition, methanol: 10 mM ammonium formate
(60:40, v/v) was selected as optimized mobile phase as it showed
best response during method development. Further, tolbutamide
(CAS: 64–77–7) and glibenclamide (CAS: 10238–21–8) were tested
as IS, and tolbutamide showed a more appropriate retention time
to ﬁnish the total analysis within 5 min. The retention time of
torasemide and IS was 3.68 min and 3.60 min, respectively.
Mass spectrometric condition was optimized so as to achieve
stable responses of analytes. In this study, ESI was selected as theFig. 3. Extraction efﬁciency with different volumes of 10% HCl.
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were evaluated to obtain optimum response of torasemide and IS.
It was found that better signal intensity was achieved withTable 2
Results of ﬁve representative calibration curves for HPLC–MS determination of torasem
Concentration added (ng/mL) Back-calculated concentration (ng/mL)
1 0.97 0.98 0.97
3 3.19 3.17 3.18
10 10.70 10.03 10.53 1
50 55.09 52.84 53.28 5
200 209.84 205.74 214.17 21
800 766.57 783.48 773.88 81
1500 1383.82 1381.15 1350.44 141
2000 1745.05 1877.51 1770.01 186
2500 2352.83 2541.92 2456.21 259
Fig. 4. Chromatograms of torasemide and the IS resulting from analysis of (A) blank
plasma, (B) blank plasma spiked with torasemide and IS, and (C) volunteer plasma.
The retention time of torasemide and the IS was 3.68 and 3.60 min, respectively.positive ion mode. However, the endogenous compounds also
have a good response, which would have an effect on analytes.
Instead of developing a method with excessive high sensitivity, we
tried to develop a bioanalytical method with good stability and
high signal-to-noise ratio. Thus, negative ion mode was selected to
ensure a better selectivity with no interference. Probe voltage was
improved to increase sensitivity. Finally, torasemide and IS were
detected at m/z 347.00 and m/z 269.00, respectively. The ion full-
scan spectra of torasemide and IS are shown in Fig. 2.3.2. Extraction optimization
The extraction was tried by both precipitating proteins and li-
quid–liquid extraction. Plasma was ﬁrst spiked with precipitating
reagents like methanol, isopropanol and butanol. However, there
was signiﬁcant interference observed from the plasma matrix in the
retention time of torasemide. Then, liquid–liquid extraction with
different solvents like ethyl acetate, ether, cyclohexane, hexane and
dichloromethane with different acid–base properties was tested.
The extraction efﬁciency of different reagents is listed in Table 1,
which indicated ethyl acetate and dichloromethane should be
chosen for further study. An orthogonal experiment of extraction
efﬁciency of ethyl acetate and dichloromethane was monitored in
different pH conditions. Table 1 shows that acid reagent performed
higher extraction. Fig. 3 shows extraction efﬁciency with different
volumes of acid solvent. The maximum response was obtained for
both torasemide and IS by adding 20 μL of acid reagents. In ﬁnal
protocol, ethyl acetate with 20 μL of 10% HCl was chosen.ide.
Mean (ng/mL) RSD (%) Mean accuracy (%)
1.01 0.98 0.98 1.67 98.20
2.89 3.24 3.13 4.44 104.47
0.15 9.76 10.23 3.71 102.34
0.97 50.11 52.46 3.75 104.92
0.06 205.42 209.05 1.72 104.52
0.69 801.13 787.15 2.34 98.39
1.66 1407.41 1386.90 1.77 92.46
7.53 1841.87 1820.39 3.27 91.02
8.71 2645.29 2518.99 4.63 100.76
Fig. 5. Chromatogram of torasemide resulting from analysis of 1ng/mL (LLOQ) of
torasemide in human plasma. The retention time of torasemide and IS was
3.68 min and 3.60 min, respectively.
Table 3
The inter- and intra-batch precision and accuracy of the method for the determination of torasemide.
Concentration added
(ng/mL)
Intra-batch (n¼5) Inter-batch (n¼15)
Concentration measured
(mean7SD) (ng/mL)
Precision
(% RSD)
Accuracy (%) Concentration measured
(mean7SD) (ng/mL)
Precision
(% RSD)
Accuracy (%)
3 2.8570.14 4.92 94.87 3.0070.30 10.07 99.90
800 830.91759.69 7.18 103.86 791.04757.01 7.32 98.88
2000 1880.91788.39 4.70 94.05 1932.597157.29 8.14 96.63
Table 4
Stability of torasemide and IS in standard solution (n¼3).
Condition of sample
analysis
Torasemide (4 ng/mL) IS (10 μg/mL)
Peak area
measured
(mean)
RSD (%) Peak area
measured
(mean)
RSD (%)
Measured immediately
(0 h)
7,332 4.24 5,948,450 2.49
Standard working solu-
tion (room tempera-
ture, 8 h)
7,707 5.27 6,181,236 2.93
Standard stock solution
(4 °C, 10 days)
8,008 4.23 6,102,100 2.51
Table 5
Stability of torasemide in human plasma at different QC levels (n¼3).
Condition of sample
analysis
Concentration measured (mean7SD) (ng/mL)
3 ng/mL 800 ng/mL 2000 ng/mL
Measured immediately
(0 h)
3.1370.36 749.26770.43 2093.477107.95
Short-term stability (8 h) 2.9870.35 704.88723.14 1940.60740.34
Residue stability (24 h) 3.2170.26 769.29744.98 2268.68724.06
Residue stability (48 h) 2.7470.20 739.03762.49 2105.737218.95
Long-term stability (15
days)
3.3370.06 803.27757.07 2212.887100.74
Post-preparative stability
(24 h)
3.0470.10 804.82734.30 2152.68771.85
Freeze and thaw stability
(ﬁrst time)
3.3370.12 815.70787.47 2196.63757.21
Freeze and thaw stability
(second time)
2.7970.11 787.85728.88 2230.56759.67
Freeze and thaw stability
(third time)
3.3670.05 839.40745.24 2106.657150.40
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3.3.1. Speciﬁcity
Six different sources of blank plasma samples were detected.
The representative chromatograms of blank plasma samples, the
plasma spiked with torasemide and IS and the plasma samples
from volunteers are shown in Fig. 4. The endogenous substances of
blank plasma samples were not interferences in the analyte.
3.3.2. Linearity, LLOQ and LOD
The method performed excellent linear response over the
concentration range of 1–2500 ng/mL by weighted least-squares
(w¼1/y2) linear regression analysis. The mean standard curve was
typically described by the equation: C¼R325.0–0.4386, with the
correlation coefﬁcientZ0.9984, where R corresponds to the peak
area ratio of torasemide to the IS, and C refers to the concentration
of torasemide in plasma. The use of the weighted regression re-
sulted in less than 15% deviation between the nominal and ex-
perimental concentrations calculated by the equation. Results of
ﬁve representative standard curves for HPLC–MS determination of
torasemide are given in Table 2. The LLOQ for torasemide was
about 1 ng/mL. Fig. 5 shows the chromatogram of LLOQ for
torasemide with the signal-to-noise ratio exceeding 10. The LOD
was about 0.5 ng/mL.
3.3.3. Precision and accuracy
The intra- and inter-batch precision and accuracy of the
method are shown in Table 3. The intra- and inter-batch precision
and accuracy ranged from 4.70% to 10.07% and from 94.05% to
103.86% at three QC levels, respectively.
3.3.4. Extraction recovery
The extraction efﬁciency of torasemide and IS in human plasma
was consistent, precise and reproducible. The mean extraction
recoveries of torasemide at each QC level (3, 800 and 2000 ng/mL)
were 86.47%78.67%, 85.54%72.86% and 84.20%72.63%, respec-
tively, and the mean extraction recovery of IS was 99.36%75.98%
at the concentration used in the analysis (10 μg/mL).3.3.5. Stability
The results of stability tests of standard stock solution, standard
working solution, as well as short-time, post-preparation, residue,
freeze and thaw, and long-time plasma samples at different QC levels
(n¼3) are shown in Tables 4 and 5. The results indicated that the
condition of sample analysis does not affect the stability of torasemide.
3.3.6. Matrix effect
To assess ionization interference from endogenous compounds
co-eluted with the analyte, matrix effect was carried out. The
mean matrix effect for torasemide at concentrations of 3, 800 and
2000 ng/mL was 102.72%78.99%, 113.22%71.49% and 109.11%
72.76%, respectively. The mean matrix effect for IS (10 μg/mL) at
three concentration levels of torasemide was 101.38%75.36%,
106.65%74.57% and 92.23%72.93%, respectively. Therefore, it
clearly proved that matrix effect of plasma was negligible in this
method. And this method was robust enough and gave accurate
and consistent results when applied in real subject samples.
3.3.7. Co-eluting effect
The co-eluting effect for torasemide at three concentration le-
vels (1, 800, 2500 ng/mL) was from 96.57% to 98.25%, and for IS
from 95.33% to 103.92% (Table 6). The results indicated that the
elution peak of IS during the run had no effect on the quantiﬁca-
tion of torasemide.
3.4. Method application
The optimized HPLC–ESI–MS method was applied in the analysis
of torasemide in human plasma after oral administration of
torasemide tablets with the dose of 10 mg by 24 healthy male volun-
teers. All the volunteers completed the study. No one presented
clinically signiﬁcant adverse effects during the present study, and all
of them were discharged in good health after repeating physical
Table 6
Results of co-eluting effects of torasemide and IS at different concentration levels
(n¼5).
Concentration (ng/mL) Torasemide IS
Accuracy (%) RSD (%) Accuracy (%) RSD (%)
1 97.38 9.49 102.34 1.93
800 96.57 0.66 95.33 0.91
2500 98.25 2.61 103.92 2.54
Fig. 6. Mean drug plasma concentration-time curve of torasemide in 24 healthy
volunteers after oral administration.
Table 7
Pharmacokinetic parameters of torasemide in 24 male volunteers after oral
administration.
Parameters Test tablets Reference tablets
Cmax (ng/mL) 1408.297337.27 1487.867360.24
Tmax (h) 0.970.4 1.070.5
t1/2 (h) 4.4370.57 4.4370.60
MRT (h) 3.9070.60 4.0170.72
AUC 0-τ (ng h/mL) 3886.867865.99 3906.067761.72
AUC 0-1 (ng h/mL) 3936.577903.93 3956.967789.98
Table 8
Comparison of the methods developed for torasemide determination in human biologic
Instrumentation Extraction
technique*
Sample vo-
lume (μL)
Linear range
(ng/mL)
Retention
time (min)
Type of
cal samp
GC–MS DþLLE 2000 50–5000 18.4 urine
HPLC–ED SPE 1000 9–7000 17.1 urine
HPLC–UV SPE 1000 20–1000 11 plasma
HPLC–UV LLE 500 50–5000 1.8 plasma
HPLC–UV PP 1000 100–4000 5.00 plasma
UPLC–UV SPE 1000 10–1000 18 Plasma &
HPLC–UV SPE 1000 60–3000 10 plasma
HPLC–UV PP 275 300–60000 6.8 plasma
HPLC–UV LLE 500 20–5000 8.4 plasma
HPLC–UV LLE 500 2000–20000 3.9 serum
HPLC–ESI–MS LLE 200 1–2500 3.68 plasma
n D: derivatization; LLE: liquid–liquid extraction; SPE: solid phase extraction; PP: pr
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The accuracy and precision of three QC level samples in the
two-period crossover study was from 96.89%74.08% to 107.14%
73.96% (Supplementary Table 1). The mean concentration of
torasemide in plasma sample versus time plot of 24 h is shown in
Fig. 6. Pharmacokinetic parameters of the test tablets and re-
ference tablets are listed in Table 7. The pharmacokinetic para-
meters including Tmax and Cmax after oral administration of
torasemide with the dose of 10 mg by healthy volunteers were
similar to those in the study by Lesne [27], which were 0.5–1.5 h
and 800–3200 ng/mL respectively. However, t1/2 and AUC of
torasemide have a deviation from our research. It results from the
lower sensitivity of determination method which cannot detect
last several points of elimination accurately.
The results from the analysis of variance found that formulation
and period had no signiﬁcant effect on AUC0-τ, AUC0-1 or Cmax at
the signiﬁcance level of 0.05. The result from Wilcoxon signed
rank test found that Tmax had no signiﬁcantly different. Therefore,
it can be concluded that the test and reference tablets are bioe-
quivalent for both the rate and the extent of absorption.3.5. Results from incurred sample reanalysis
The reproducibility of the determination was studied by re-
analysis of incurred samples (Supplementary Tables 2 and 3). The
percentage difference in two assay periods was from 18.56% to
15.81%, which was within the acceptance criterion of 720% [24].
The result showed that the reported concentrations of torasemide
in human plasma measured by this method were reliability.3.6. Comparison with other methods
A detailed comparison of methods for the determination of
torasemide in human biological samples is showed in Table 8. The
developed method of the study is more sensitive than all other
methods developed for determination of torasemide as a single
analyte in human plasma [9–21]. In addition, the proposed
method uses less plasma (200 μL) than many other reported
methods, and has better human compliance for volunteers in
bioequivalence and pharmacokinetic studies.al samples.
biologi-
les
Application Refs.
Determination of torasemide in urine obtained from a health
volunteer after a single dose
[9]
Analysis the torasemide and its metabolite M5 in urine sample
after a single dose
[21]
Determination of torasemide and its important metabolites [11]
Measurement of the torasemide concentration in plasma from
healthy subject after a single dose
[16]
Bioequivalence study of 20 mg torasemide in 12 healthy
volunteers
[12]
urine Determination of torasemide and its two metabolites in plasma
and urine
[13]
Determination of torasemide and its two metabolites in plasma [15]
Determination of torasemide and spironolactone in plasma [17]
Bioequivalence study of 10 mg torasemide in 28 healthy
volunteers
[18]
Pharmaceutical research of torasemide in 5 hypertensive
patients
[19]
Bioequivalence study of 10 mg torasemide in 24 healthy vo-
lunteers & reanalysis of 54 incurred samples
This
study
otein precipitation
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Only few methods were reported on the determination of the
concentration of torasemide in human plasma by HPLC–MS. In this
research, a sensitive and selective HPLC–ESI–MS method for the
determination of torasemide in human plasma samples was de-
veloped. This method used fewer plasma samples to bring out
wider linear range and better human compliance. This method
was validated according to bioanalytical method validation and
successfully applied in pharmacokinetic and bioequivalence stu-
dies on torasemide in human volunteers.Acknowledgments
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